Evidence map›Paper›PMID 35812555›Full record

ArticleCureus2022

Proton Beam Therapy for Multifocal Hepatocellular Carcinoma (HCC) Showing Complete Response in Pathological Anatomy After Liver Transplantation.

Yinuo Li, Shosei Shimizu, Masashi Mizumoto, Takashi Iizumi, Haruko Numajiri, Hirokazu Makishima, Gong Li, Hideyuki Sakurai

Abstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yinuo LiDepartment of Radiation Oncology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, JPN.
Shosei ShimizuDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, JPN.
Masashi MizumotoDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, JPN.
Takashi IizumiDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, JPN.
Haruko NumajiriDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, JPN.
Hirokazu MakishimaDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, JPN.
Gong LiDepartment of Radiotherapy, Beijing Tsinghua Changgung Hospital, Beijing, CHN.
Hideyuki SakuraiDepartment of Radiation Oncology, Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a patient with multifocal recurrent hepatocellular carcinoma (HCC) who received proton beam therapy (PBT) and then underwent donation after brain dead (DBD) liver transplantation. The anatomy of the explanted diseased liver was examined pathologically post-transplantation. The patient was a 52-year-old male with hepatitis B virus infection and liver cirrhosis of Child-Pugh class B. Right lobe and caudate lobectomy were performed for primary HCC. However, three recurrent tumors appeared in the remnant liver in segments S2 (two sites) and S4, of sizes 23 mm, 10 mm, and 32 mm, respectively. Liver transplantation was required due to these multiple HCCs and liver cirrhosis, but the patient was ineligible for living donor liver transplantation (LDLT) based on Milan criteria. He was registered as a candidate on the waiting list for DBD transplantation. In consideration of the long waiting time for a deceased donor transplant for more than one year, the progression of multiple recurrent HCCs, and the risk of death, the patient had limited treatment options other than PBT for poor liver function and multifocal HCC and eventually received 65 GyE/18 fractions of PBT. Eleven months after the start of PBT, the tumors remained progression-free and liver function did not deteriorate, allowing the patient to wait for liver transplantation. After transplantation, the histopathology of the explanted liver showed that the left lobe of the liver treated by PBT showed no evidence of solid tumors and tumor cells in visual and microscopic examinations. There was also no significant damage to normal liver tissue. This case demonstrates that PBT is a prospective option for patients with HCC with poor liver function, multiple tumors, and no other treatment options. PBT can achieve control or even complete response of HCC while maintaining liver function and may be an effective pre-transplant method for tumor downstaging and prolonging survival. PBT may enable more people to wait for a donor liver or to become eligible for liver transplantation.

Indexed as

hepatocellular carcinomaliver cirrhosisliver transplantationpathological anatomyproton beam therapyradiation

Identifiers

PMID35812555
PMCPMC9264287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.